NCT03203564 - Study Evaluating ECG Effects, Safety, Tolerability and Pharmacokinetics of Single Doses of Modufolin (Arfolitixorin) in Healthy Volunteers Tetrahydrofolate in Healthy Male Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 4, 2017

Primary Completion Date

August 25, 2017

Study Completion Date

August 25, 2017

Conditions

Phase I Study in Healthy Volunteers to Evaluate ECG Effect

Interventions

DRUG

Modufolin (arfolitixorin)

Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)

Trial Locations (1)

75185

CTC Clinical Trial Consultants, Uppsala